Design over discovery.

That’s the tagline Aridni Shah of ImmunitoAI doesn’t want you to glaze over. In drug discovery—where thousands of molecules are screened, tested, and mostly discarded, and where 90% of what does survive eventually fails in clinical trials—Shah and her co-founder Trisha Chatterjee are trying to tilt the odds. Calculatedly, because India punishes this pursuit. Economically, because domestic risk capital won’t touch it.

“In less than five months, in a single........

© The Ken